

Mark N Kirstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4064647/publications.pdf>

Version: 2024-02-01

27
papers

860
citations

758635

12
h-index

525886

27
g-index

28
all docs

28
docs citations

28
times ranked

1260
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive Value of C-reactive Protein and Albumin for Temporal Within-Individual Pharmacokinetic Variability of Voriconazole in Pediatric Patients Undergoing Hematopoietic Cell Transplantation. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 855-862.	1.0	3
2	CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0062321.	1.4	12
3	A phase I dose finding study of intravenous voriconazole in pediatric patients undergoing hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 955-964.	1.3	7
4	Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	4
5	Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 387-391.	1.1	5
6	Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 773-783.	1.1	12
7	Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning. <i>Translational Research</i> , 2016, 175, 103-115.e4.	2.2	22
8	Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS). <i>Breast Cancer Research and Treatment</i> , 2016, 155, 501-512.	1.1	35
9	Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors. <i>Pharmacogenomics</i> , 2012, 13, 1009-1021.	0.6	26
10	Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine. <i>AAPS Journal</i> , 2012, 14, 1-9.	2.2	11
11	Severe Electrolyte Disturbances After Hyperthermic Intraperitoneal Chemotherapy: Oxaliplatin Versus Mitomycin C. <i>Annals of Surgical Oncology</i> , 2011, 18, 174-180.	0.7	34
12	Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 721-731.	1.1	14
13	Combinatorial Pharmacologic Effects of Gemcitabine and its Metabolite dFdU. <i>ChemMedChem</i> , 2011, 6, 457-464.	1.6	6
14	Phase 1 Trial of Gemcitabine With Bortezomib in Elderly Patients With Advanced Solid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 597-602.	0.6	7
15	Enhanced Sensitivity Method for Measuring Gemcitabine in Human Plasma. <i>Chromatographia</i> , 2010, 72, 1005-1008.	0.7	1
16	Cap-dependent translation blockade and fixed dose-rate gemcitabine: Interaction in an in vitro bioreactor system. <i>Cancer Letters</i> , 2009, 284, 37-46.	3.2	6
17	Exposure-response relationships for oxaliplatin-treated colon cancer cells. <i>Anti-Cancer Drugs</i> , 2008, 19, 37-44.	0.7	24
18	Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system. <i>Lung Cancer</i> , 2007, 58, 196-204.	0.9	6

#	ARTICLE	IF	CITATIONS
19	Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 61, 291-299.	1.1	17
20	Review of Selected Patents for Cancer Therapy Targeting Tumor Angiogenesis. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 153-161.	0.8	7
21	High-performance liquid chromatographic method for the determination of gemcitabine and 2â€²,2â€²-difluorodeoxyuridine in plasma and tissue culture media. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 835, 136-142.	1.2	59
22	Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens. <i>Breast Cancer Research and Treatment</i> , 2006, 96, 217-225.	1.1	14
23	Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 55, 433-438.	1.1	8
24	Topoisomerase I interactive agents. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2002, 20, 99-123.	0.5	5
25	Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. <i>Cancer Chemotherapy and Pharmacology</i> , 2001, 47, 89-93.	1.1	16
26	Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 269-276.	1.1	42
27	ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). <i>Oncogene</i> , 1997, 14, 2175-2188.	2.6	455